Abbott Axsym B-Type Natriuretic Peptide (Bnp) Microparticle Enzyme Immunoassay (Meia) Test
Test, Natriuretic Peptide. 510(k) K033606, from Axis-Shield Diagnostics, Ltd. (Dundee, Scotland, GB). Product code NBC, class 2.
As of Nov 19, 2026, K033606 is an FDA 510(k) held by Axis-Shield Diagnostics, Ltd., substantially equivalent on Jan 30, 2004 after 74 days, with no recalls tied to it in FDA's recall database.
- Review time: 74 days
- Recalls: 0
- Cited as a predicate by: 1 device
AxSYM® BNP is a Microparticle Enzyme Immunoassay (MEIA) for the quantitative determination of human B-type natriuretic peptide in human EDTA plasma on the AxSYM System. BNP values are used as an aid in the diagnosis and assessment of severity of heart failure.
- Triage B-Type Natriuretic Peptide (Bnp) TestK021317 · Biosite Incorporated · Jul 1, 2002
- Architect Bnp Assay, Model 8K28K060964 · Fujirebio Diagnostics,Inc. · May 25, 2006
- Access BNP IIK262597 · Beckman Coulter, Inc. · Oct 20, 2026
- Access NT-proBNPK262109 · Beckman Coulter, Inc. · Sep 21, 2026
- Access BNP IIK252169 · Beckman Coulter, Inc. · Mar 24, 2026
- Alere NT-proBNP for Alinity iK253539 · Axis-Shield Diagnostics, Ltd. · Feb 18, 2026
- Alere NT-proBNP for Alinity i Reagent KitK241176 · Axis-Shield Diagnostics, Ltd. · Jan 16, 2025
- Access NT-proBNPK232164 · Beckman Coulter, Inc. · Apr 12, 2024
- ADVIA Centaur® NT-proBNPII (PBNPII)K220265 · Siemens Healthcare Diagnostics, Inc. · Sep 24, 2023
- Elecsys proBNP II, Elecsys proBNP II STATK223637 · Roche Diagnostics · Jul 21, 2023
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Nov 17, 2003
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1117
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files